Advanced Clinical Stage Chemomab is at a pivotal point in clinical development with positive Phase 2 data and preparations for a Phase 3 trial for nebokitug targeting primary sclerosing cholangitis, indicating a high potential for upcoming regulatory approvals and market entry opportunities.

Strong Regulatory Support The company has secured FDA and EMA Orphan Drug status as well as Fast Track designation for nebokitug, which can accelerate market access and provide incentives for healthcare providers and payers.

Industry Engagement Active participation in industry events such as rare disease summits and major clinical conferences demonstrates Chemomab’s visibility and opportunity to connect with specialists, investors, and strategic partners focused on fibro-inflammatory diseases.

Market Potential Targeting multiple high-unmet-need fibro-inflammatory conditions like PSC and systemic sclerosis positions Chemomab to address a broad patient population, creating expansive sales opportunities across specialty clinics and hospitals.

Financial & Funding Standing With recent funding of around $15 million and revenue estimates between $10 million and $25 million, Chemomab is positioned for further growth and business development activities, making it an attractive partner or investment opportunity for future collaboration.